| Faculty and Alumni to Receive Alumni Association Awards | | Posted Thursday, October 12, 2006 3:02:34 AM by Blog57 Team | | At noon on Friday, the Medical Alumni Association will host a luncheon for alumni and invited guests. The association will present the following awards: Distinguished Faculty Award Robert M. Califf , MD, Donald F. Fortin Professor of Cardiology; vice chancellor for clinical research; and Director, Duke Clinical Research Institute. An international expert on evidence-based medicine, Califf created the Duke Clinical Research institute, the world's largest clinical research organization . Paul G. Killenberg , MD, Professor Emeritus of Medicine, Division of Gastroenterology, Duke University Medical Center. Killenberg helped create Duke's Liver Transplant Program—the first in North Carolina—and has served as interim chief of the Division of Gastroenterology.... | |
| |
| | | Heart Risks Offset Polyp Prevention Benefit for Celebrex | | Posted Thursday, August 31, 2006 4:57:09 AM by Blog57 Team | | BOSTON, Aug. 30 -- Celebrex (celecoxib) can prevent sporadic colorectal adenomas, as well as reduce post-polypectomy recurrences, but these pluses may by outweighed by cardiovascular minuses. Moreover, neither of the two trials reported in the Aug. 31 issue of the New England Journal of Medicine trial was powered to determine a role for Celebrex in the prevention of colon cancer. Nonetheless, reductions in polyps observed in both the APC study (Adenoma Prevention with Celecoxib) and the PreSAP (Prevention of Colorectal Sporadic Adenomatous Polyps) were significant. Surgical oncologist Monica M. Bertagnolli, M.D., of Brigham and Women's Hospital here and her ACP co-investigators reported that three years of treatment with 200 mg of Celebrex twice daily reduced the rate of detectable polyps by 33% and 400 mg twice daily reduced rate by 45%, compared with placebo (P for both).... | |
| |
| | | How tumors respond to treatment prior to liver transplants may be useful in selecting recipients | | Posted Wednesday, August 02, 2006 2:59:14 AM by Blog57 Team | | Liver transplantation is widely recognized as an effective treatment for early-stage hepatocellular carcinoma (HCC) and the size and number of tumors, known as the Milan criteria, are traditionally used to determine a patient's eligibility for a transplant. Treating tumors prior to transplant has been used as a strategy to bridge the waiting time before an organ becomes available, but little research has been conducted on whether pre-treatment may influence survival. Led by Gerd Otto, M.D. of the Department of Transplantation and Hepatobiliopancreatic Surgery at Johannes Gutenberg University in Mainz, Germany, researchers selected 96 HCC patients between May 1996 and May 1998 for periodic transarterial chemoembolization (TACE) prior to liver transplantation. TACE is a treatment where agents designed to halt or reduce tumor growth are injected into the artery supplying the tumor.... | |
| |
| | | National Surgical Care Partners With Two Endoscopy Centers in ... | | Posted Saturday, July 01, 2006 5:05:01 AM by Blog57 Team | | CHICAGO, June 27 /PRNewswire/ -- National Surgical Care ("NSC"), which partners with physicians and healthcare systems across the country to develop, own and operate surgical facilities, today announced a partnership with Austin Gastroenterology P.A., a medical group consisting of 19 board certified gastroenterologists. The partnership involves the ownership and management of two endoscopy centers in Austin, Texas. Terms of the transaction were not disclosed. Austin Gastroenterology is the largest group of physicians specializing in the diagnosis, treatment and prevention of gastrointestinal diseases in Central Texas with 10 offices in the greater Austin market. In 2001, Austin Gastroenterology opened the first surgery center in the Austin area dedicated solely to the care of gastroenterology patients and the diagnosis, treatment and prevention of gastrointestinal disease.... | |
| |
| |
|
|
